Yumanity Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Richard Peters
Chief executive officer
US$4.5m
Total compensation
| CEO salary percentage | 13.8% |
| CEO tenure | 2yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$4m | US$618k | -US$40m |
Compensation vs Market: Richard's total compensation ($USD4.49M) is above average for companies of similar size in the US market ($USD738.70K).
Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.
CEO
Richard Peters (59 yo)
2yrs
Tenure
US$4,494,240
Compensation
Dr. Richard Peters, M.D., Ph D., is a Founder at X4 Pharmaceuticals, Inc. He serves as Independent Director at Aprea Therapeutics AB since July 2020. He served as Director of PIC Therapeutics Inc. He Co-Fo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$4.49m | 0.55% $ 787.9k | |
| Scientific Co-Founder & Senior Advisor of Discovery Biology | 5.1yrs | no data | no data | |
| Scientific Co-Founder & Associate Director of Discovery Biology | 5.1yrs | no data | no data | |
| Vice President of Finance | no data | no data | 0.082% $ 117.5k | |
| SVP, CFO & Treasurer | 1.3yrs | no data | 0.13% $ 185.2k | |
| SVP, General Counsel & Secretary | 1.5yrs | no data | 0.13% $ 184.7k |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: YMTX's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$4.49m | 0.55% $ 787.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$198.30k | 0% $ 0 | |
| Non-Executive Chairman | 2yrs | US$1.53m | 6.85% $ 9.8m | |
| Lead Independent Director | 2yrs | US$242.35k | 0.075% $ 107.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$209.80k | 0% $ 0 | |
| Independent Director | 2yrs | US$194.80k | 0.12% $ 174.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.0yrs
Average Tenure
62.5yo
Average Age
Experienced Board: YMTX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/19 23:23 |
| End of Day Share Price | 2022/12/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yumanity Therapeutics, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |
| Kelechi Chikere | Jefferies LLC |